Print
Mail
The early research focus at Movetis is on the discovery of new compounds that influence GI motility with the most favourable benefit/safety profile and on novel compounds that inhibit secretion in the lower GI tract.
Project in the preclinical portfolio include M0012, a 5-HT3 receptor agonist targeting c-IBS and M0014, a 5-HT4 receptor antagonist targeting chronic anti-inflammatory states in GI diseased such as certain subtypes of IBS.
Movetis will seek to generate proof of concept data and then decide on the optimal strategy for further development.
